|
1
|
Palella FJ Jr, Baker RK, Moorman AC,
Chmiel JS, Wood KC, Brooks JT and Holmberg SD: HIV Outpatient Study
Investigators. Mortality in the highly active antiretroviral
therapy era: Changing causes of death and disease in the HIV
outpatient study. J Acquir Immune Defic Syndr. 43:27–34.
2006.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Crum NF, Riffenburgh RH, Wegner S, Agan
BK, Tasker SA, Spooner KM, Armstrong AW, Fraser S and Wallace MR:
Triservice AIDS Clinical Consortium. Comparisons of causes of death
and mortality rates among HIV-infected persons: Analysis of the
pre-, early, and late HAART (highly active antiretroviral therapy)
eras. J Acquir Immune Defic Syndr. 41:194–200. 2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ipp H, Zemlin AE, Erasmus RT and Glashoff
RH: Role of inflammation in HIV-1 disease progression and
prognosis. Crit Rev Clin Lab Sci. 51:98–111. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Appay V and Sauce D: Immune activation and
inflammation in HIV-1 infection: Causes and consequences. J Pathol.
214:231–241. 2008.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Engelmann B and Massberg S: Thrombosis as
an intravascular effector of innate immunity. Nat Rev Immunol.
13:34–45. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Gaertner F and Massberg S: Blood
coagulation in immunothrombosis-At the frontline of intravascular
immunity. Semin Immunol. 28:561–569. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Martinod K and Deppermann C:
Immunothrombosis and thromboinflammation in host defense and
disease. Platelets. 32:314–324. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gresele P, Falcinelli E, Sebastiano M and
Baldelli F: Endothelial and platelet function alterations in
HIV-infected patients. Thromb Res. 129:301–308. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Awamura T, Nakasone ES, Gangcuangco LM,
Subia NT, Bali AJ, Chow DC, Shikuma CM and Park J: Platelet and HIV
interactions and their contribution to non-AIDS comorbidities.
Biomolecules. 13(1608)2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Jackson BS and Pretorius E: Pathological
clotting and deep vein thrombosis in patients with HIV. Semin
Thromb Hemost. 45:132–140. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Funderburg NT, Mayne E, Sieg SF, Asaad R,
Jiang W, Kalinowska M, Luciano AA, Stevens W, Rodriguez B,
Brenchley JM, et al: Increased tissue factor expression on
circulating monocytes in chronic HIV infection: Relationship to in
vivo coagulation and immune activation. Blood. 115:161–167.
2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kapoor S, Opneja A and Nayak L: The role
of neutrophils in thrombosis. Thromb Res. 170:87–96.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bibas M, Biava G and Antinori A:
HIV-associated venous thromboembolism. Mediterr J Hematol Infect
Dis. 3(e2011030)2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hunt P: HIV and inflammation: Mechanisms
and consequences. Curr HIV/AIDS Rep. 9:139–147. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Canyelles M, Borràs C, Rotllan N, Tondo M,
Escolà-Gil JC and Blanco-Vaca F: Gut microbiota-derived TMAO: A
causal factor promoting atherosclerotic cardiovascular disease? Int
J Mol Sci. 24(1940)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Huang K, Li Z, He X, Dai J, Huang B, Shi
Y, Fan D, Zhang Z, Liu Y, Li N, et al: Gut microbial co-metabolite
2-methylbutyrylcarnitine exacerbates thrombosis via binding to and
activating integrin α2β1. Cell Metab. 36:598–616.e9.
2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang Z, Peters BA, Usyk M, Xing J, Hanna
DB, Wang T, Post WS, Landay AL, Hodis HN, Weber K, et al: Gut
microbiota, plasma metabolomic profiles, and carotid artery
atherosclerosis in HIV infection. Arterioscler Thromb Vasc Biol.
42:1081–1093. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Nkambule BB, Mxinwa V, Mkandla Z, Mutize
T, Mokgalaboni K, Nyambuya TM and Dludla PV: Platelet activation in
adult HIV-infected patients on antiretroviral therapy: A systematic
review and meta-analysis. BMC Med. 18(357)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mesquita EC, Hottz ED, Amancio RT,
Carneiro AB, Palhinha L, Coelho LE, Grinsztejn B, Zimmerman GA,
Rondina MT, Weyrich AS, et al: Persistent platelet activation and
apoptosis in virologically suppressed HIV-infected individuals. Sci
Rep. 8(14999)2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kiebala M, Singh MV, Piepenbrink MS, Qiu
X, Kobie JJ and Maggirwar SB: Platelet activation in human
immunodeficiency virus type-1 patients is not altered with cocaine
abuse. PLoS One. 10(e0130061)2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
O'Halloran JA, Dunne E, Gurwith M, Lambert
JS, Sheehan GJ, Feeney ER, Pozniak A, Reiss P, Kenny D and Mallon
P: The effect of initiation of antiretroviral therapy on monocyte,
endothelial and platelet function in HIV-1 infection. HIV Med.
16:608–619. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Schechter ME, Andrade BB, He T, Richter
GH, Tosh KW, Policicchio BB, Singh A, Raehtz KD, Sheikh V, Ma D, et
al: Inflammatory monocytes expressing tissue factor drive SIV and
HIV coagulopathy. Sci Transl Med. 9(eaam5441)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Tunjungputri RN, Van Der Ven AJ,
Schonsberg A, Mathan TS, Koopmans P, Roest M, Fijnheer R, Groot PG
and de Mast Q: Reduced platelet hyperreactivity and
platelet-monocyte aggregation in HIV-infected individuals receiving
a raltegravir-based regimen. AIDS. 28:2091–2096. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Jaschinski N, Greenberg L, Neesgaard B,
Miró JM, Grabmeier-Pfistershammer K, Wandeler G, Smith C, De Wit S,
Wit F, Pelchen-Matthews A, et al: Recent abacavir use and incident
cardiovascular disease in contemporary-treated people with HIV.
AIDS. 37:467–475. 2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Du M, Zhang S, Liu M and Liu J:
Cardiovascular disease and its risk factors among people living
with HIV: A systematic review and meta-analysis. J Infect Public
Health. 18(102654)2025.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Blanch-Ruíz MA, Sánchez-López A,
Ríos-Navarro C, Ortega-Luna R, Collado-Díaz V, Orden S,
Martínez-Cuesta MA, Esplugues JV and Álvarez Á: Abacavir causes
leukocyte/platelet crosstalk by activating neutrophil P2X7
receptors thus releasing soluble lectin-like oxidized low-density
lipoprotein receptor-1. Br J Pharmacol. 180:1516–1532.
2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yan Q, Huang S, van der Heijden W,
Ninivaggi M, van de Wijer L, de Laat-Kremers R, Van der Ven AJ, de
Laat B and de Mast Q: Abacavir use is associated with increased
prothrombin conversion. Front Immunol. 14(1182942)2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Neesgaard B, Greenberg L, Miró JM,
Grabmeier-Pfistershammer K, Wandeler G, Smith C, De Wit S, Wit F,
Pelchen-Matthews A, Mussini C, et al: Associations between
integrase strand-transfer inhibitors and cardiovascular disease in
people living with HIV: A multicentre prospective study from the
RESPOND cohort consortium. Lancet HIV. 9:e474–e485. 2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ntsekhe M and Baker JV: Cardiovascular
disease among persons living with HIV: New insights into
pathogenesis and clinical manifestations in a global context.
Circulation. 147:83–100. 2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Dentali F, Nicolini E and Ageno W: Venous
and arterial thrombosis associated with HIV infection. Semin Thromb
Hemost. 38:524–529. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
De Gaetano Donati K, Rabagliati R,
Tumbarello M, Tacconelli E, Amore C, Cauda R and Lacoviello L:
Increased soluble markers of endothelial dysfunction in
HIV-positive patients under highly active antiretroviral therapy.
AIDS. 17:765–768. 2003.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Smith GHR, Henry WK, Podzamczer D, Masiá
MDM, Bettacchi CJ, Arasteh K, Jaeger H, Khuong-Josses MA,
Montes-Ramírez ML, Stellbrink HJ, et al: Efficacy, safety, and
durability of long-acting cabotegravir and rilpivirine in adults
with human immunodeficiency virus type 1 infection: 5-Year results
from the LATTE-2 study. Open Forum Infect Dis.
8(ofab439)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Heit JA: Epidemiology of venous
thromboembolism. Nat Rev Cardiol. 12:464–474. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Sullivan PS, Dworkin MS, Jones JL and
Hooper WC: Epidemiology of thrombosis in HIV-infected individuals.
The adult/adolescent spectrum of HIV disease project. AIDS.
14:321–324. 2000.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Rasmussen LD, Dybdal M, Gerstoft J,
Kronborg G, Larsen CS, Pedersen C, Pedersen G, Jensen J, Pedersen
L, Sørensen HT and Obel N: HIV and risk of venous thromboembolism:
A Danish nationwide population-based cohort study. HIV Med.
12:202–210. 2011.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Rokx C, Borjas Howard JF, Smit C, Wit FW,
Pieterman ED, Reiss P, Cannegieter SC, Lijfering WM, Meijer K,
Bierman W, et al: Risk of recurrent venous thromboembolism in
patients with HIV infection: A nationwide cohort study. PLoS Med.
17(e1003101)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Shaw ML: Persons living with HIV have a
higher risk of recurrent blood clots, 2020.
|
|
38
|
Netravathi M, Jaychandran R, Bhat M,
Christopher R and Satishchandra P: Profile of 26 HIV seropositive
individuals with cerebral venous thrombosis. J Neurol Sci.
378:69–74. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Ramanampamonjy RM, Ramarozatovo LS, Bonnet
F, Lacoste D, Rambeloarisoa J, Bernard N, Beylot J and Morlat P:
Portal vein thrombosis in HIV-infected patients: Report of four
cases. Rev Med Interne. 26:545–548. 2005.PubMed/NCBI View Article : Google Scholar : (In French).
|
|
40
|
Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam
S, Clifford S, Longenecker CT, Strachan F, Bagchi S, Whiteley W, et
al: Global burden of atherosclerotic cardiovascular disease in
people living with HIV: Systematic review and meta-analysis.
Circulation. 138:1100–1112. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Rodger AJ, Lodwick R, Schechter M, Deeks
S, Amin J, Gilson R, Paredes R, Bakowska E, Engsig FN, Phillips A,
et al: Mortality in well controlled HIV in the continuous
antiretroviral therapy arms of the SMART and ESPRIT trials compared
with the general population. AIDS. 27:973–979. 2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Perkins MV, Joseph SB, Dittmer DP and
Mackman N: Cardiovascular disease and thrombosis in HIV infection.
Arterioscler Thromb Vasc Biol. 43:175–191. 2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Islam FM, Wu J, Jansson J and Wilson DP:
Relative risk of cardiovascular disease among people living with
HIV: A systematic review and meta-analysis. HIV Med. 13:453–468.
2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Gutierrez J, Albuquerque ALA and Falzon L:
HIV infection as vascular risk: A systematic review of the
literature and meta-analysis. PLoS One. 12(e0176686)2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Eyawo O, Brockman G, Goldsmith CH, Hull
MW, Lear SA, Bennett M, Guillemi S, Franco-Villalobos C, Adam A,
Mills EJ, et al: Risk of myocardial infarction among people living
with HIV: An updated systematic review and meta-analysis. BMJ Open.
9(e025874)2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Qureshi AI, Janssen RS, Karon JM, Weissman
JP, Akbar MS, Safdar K and Frankel MR: Human immunodeficiency virus
infection and stroke in young patients. Arch Neurol. 54:1150–1153.
1997.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Bogorodskaya M, Chow FC and Triant VA:
Stroke in HIV. Can J Cardiol. 35:280–287. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Chow FC, Bacchetti P, Kim AS, Price RW and
Hsue PY: Effect of CD4+ cell count and viral suppression on risk of
ischemic stroke in HIV infection. AIDS. 28:2573–2577.
2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Becker S, Fusco G, Fusco J, Balu R,
Gangjee S, Brennan C and Feinberg J: Collaborations in HIV Outcomes
Research/US Cohort. HIV-associated thrombotic microangiopathy in
the era of highly active antiretroviral therapy: An observational
study. Clin Infect Dis. 39 (Suppl 5):S267–S275. 2004.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Louw S, Gounden R and Mayne ES: Thrombotic
thrombocytopenic purpura (TTP)-like syndrome in the HIV era. Thromb
J. 16(35)2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Meiring M, Webb M, Goedhals D and Louw V:
HIV-associated thrombotic thrombocytopenic purpura-what we know so
far. Eur Oncol Haematol. 8:89–91. 2012.
|
|
52
|
Thompson GR III, Lawrence VA and Crawford
GE: HIV infection increases the risk of heparin-induced
thrombocytopenia. Clin Infect Dis. 45:1393–1396. 2007.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Zhang Q, Peng F, Li M, Yi Q, Tang W and Wu
S: Elevated risk of venous thromboembolism in people living with
HIV. Viruses. 14(590)2022.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Ridker PM, Everett BM, Thuren T, MacFadyen
JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker
SD, et al: Antiinflammatory therapy with canakinumab for
atherosclerotic disease. N Engl J Med. 377:1119–1131.
2017.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Jacobsson LTH, Turesson C, Gülfe A,
Kapetanovic MC, Petersson IF, Saxne T and Geborek P: Treatment with
tumor necrosis factor blockers is associated with a lower incidence
of first cardiovascular events in patients with rheumatoid
arthritis. J Rheumatol. 32:1213–1218. 2005.PubMed/NCBI
|
|
56
|
Gabay C, Burmester GR, Strand V, Msihid J,
Zilberstein M, Kimura T, van Hoogstraten H, Boklage SH, Sadeh J,
Graham NMH and Boyapati A: Sarilumab and adalimumab differential
effects on bone remodelling and cardiovascular risk biomarkers, and
predictions of treatment outcomes. Arthritis Res Ther.
22(70)2020.PubMed/NCBI View Article : Google Scholar
|
